MedTrace Logo

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

NCT00654238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2019-11-18

Study results available
· View outcomes & findings →

Summary

The goal of this study is to determine the activity of sorafenib in patients with advanced (metastatic or recurrent) thyroid cancer.

Conditions

  • Metastatic Differentiated Thyroid Cancer
  • Metastatic Poorly Differentiated Thyroid Cancer
  • Metastatic Anaplastic Thyroid Cancer
  • Metastatic Medullary Thyroid Cancer

Interventions

DRUG

sorafenib

400mg PO BID daily

Sponsors & Collaborators

Principal Investigators

  • Marcia S Brose, MD PhD · Unviersity of Pennsylvania - Abramson Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2010-12-31
Completion
2011-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00654238 on ClinicalTrials.gov